Cencora Raises FY26 EPS Outlook on Specialty Momentum, but Cost and Buyback Risks Persist

What happened

Cencora raised its fiscal 2026 EPS outlook again, citing strengthening specialty businesses, particularly OneOncology, as offsetting persistent revenue headwinds from manufacturer list-price reductions and customer mix degradation. This aligns with prior disclosures that gross margin improved roughly 45 basis points to 4.31% on OneOncology mix, while list-price cuts reduced revenue by $2 billion in the second quarter. However, the raised guidance does not eliminate execution risk: DS&A remains elevated at 2.52% of revenue and deal/integration costs ran $164 million in Q2, with no proof of near-term fade. Buyback execution remains unproven through March (zero repurchases) despite a stated $1 billion target by December 31, 2026, and acquisition-related interest expense adds financing pressure. At $287.7, the stock sits inside the WAIT zone, and the headline only keeps the bull case alive without resolving margin/opex or capital-return proof points.

Implication

The raised guidance is modestly positive but does not alter the thesis because the same risks—customer mix, DS&A deleverage, and interest expense—remain unresolved. Investors should monitor FY2026 Q3 results (expected around September 23, 2026) for a sequential decline in integration costs from $164 million and DS&A below 2.45%. Failure to show cost fade or meaningful buyback progress toward $1 billion by December 31, 2026 would shift the base case toward the bear $250 scenario. Conversely, evidence of sustained gross margin above 4.30% plus repurchase execution could support a move toward $310–$330. Until then, position sizing should remain disciplined, waiting for operating confirmation rather than extrapolating a positive headline.

Thesis delta

The guidance raise itself is incremental and consistent with our base case, and it does not materially shift probability weights. The key delta is that specialty strength is now explicitly credited for the raise, which modestly supports the bull scenario's gross margin assumption, but the bear case's DS&A and financing pressures remain unresolved. We keep WAIT and require Q3 data to confirm that cost fade and buybacks are real before adjusting conviction or entry point.